Journal of Clinical Oncology

Papers
(The H4-Index of Journal of Clinical Oncology is 134. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Radiation therapy and associated cardiovascular outcomes in patients with Hodgkin’s lymphoma.1285
A randomized trial of topical cannabis balms for the treatment of aromatase inhibitor–associated musculoskeletal syndrome (AIMSS).902
Ubiquitin ligase subunit FBXO9 inhibits V-ATPase assembly and lung cancer metastasis.873
Clinical outcomes and prognostic factors in epithelial-myoepithelial carcinoma (EMC) of the breast.630
STELLAR-305: A randomized phase 2/3 study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with previously untreated PD-L1 positive recurrent/metastatic head and neck squamou628
Circulating tumor DNA analysis in patients with BRAF-mutated metastatic cutaneous melanoma treated with BRAF and MEK inhibitors: Analysis of the OPTIMEL study.543
Patient characteristics, treatment patterns and early trends of lutetium Lu 177 vipivotide tetraxetan (177Lu-PSMA-617) use by US urologists and oncologists.536
Health state utility assessment for low-grade glioma.513
Association of a clinical model based on skeletal muscle radiation attenuation with efficacy for patients with gastric cancer treated with chemotherapy plus PD-1 antibodies: A single-center retrospect492
Prognostic indicators of recurrence after surgical resection in non-pancreatic gastrointestinal neuroendocrine tumors.482
Phase II study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors.482
5-hydroxymethylcytosine in cell-free DNA as liquid biomarker for immune checkpoint inhibitor therapy in non–small cell lung cancer.480
Portal vein thrombosis in gastrointestinal cancers: Insights into prevalence and prognosis—A nationwide inpatient analysis 2018-2020.477
Percutaneous cryoablation of breast cancer metastases: Analysis of long-term single center experience, efficacy and outcomes.433
Longitudinal changes in triceps skinfold thickness and serum albumin during chemotherapy in patients with pancreatic cancer: Gender-based prognostic insights—A prospective cohort study.410
FOLFOX as a therapeutic option in patients with hepatic failure due to liver metastasis of gastrointestinal (GI) system malignancies: A case series.381
Genomic and immune landscape of biliary tract cancers with ARID1A, PBRM1, and BAP1 alterations.380
Improved survival from early combined radiotherapy: A phase II clinical study and underlying mechanisms of delaying EGFR-TKI acquired resistance in patients with advanced lung cancer.365
Effect of cerebral dopamine metabolism genetic polymorphism on patient-reported quality-of-life (QOL): An analysis of the E3805 CHAARTED trial.363
DNA damaging therapies in patients (pts) with prostate cancer (PC) and pathogenic alterations in homologous recombination repair (HRR) genes.361
Subgroup analysis in RE-MIND2, an observational, retrospective cohort study of tafasitamab plus lenalidomide versus systemic therapies in patients with relapsed/refractory diffuse large B-cell lymphom338
Feasibility of a child life specialist program for oncology patients with minor children at home: Qualitative analysis.330
Phase II study of nivolumab (nivo) with relatlimab (rela) in patients (pts) with first-line advanced melanoma: Early on-treatment major pathologic response on biopsy.328
Systematic Review on Electronic Health Interventions for Patients With Breast Cancer: Revisiting the Methodology325
A platform for high-resolution immune liquid biopsy analysis to predict response in patients with renal cell carcinoma treated with nivolumab or cabozantinib: Preliminary data from I-RENE trial (Meet-317
A phase Ib/II study (IMMCO-1) of atezolizumab plus tivozanib in immunologically cold pancreatic, gallbladder, and biliary cancers.315
Comprehensive genomic profiling (CGP)-informed personalized molecular residual disease (MRD) detection: An exploratory analysis from the PREDATOR study of metastatic colorectal cancer (mCRC) patients 310
A phase 1/2 study of REGN4336, a PSMAxCD3 bispecific antibody, alone and in combination with cemiplimab in patients with metastatic castration-resistant prostate cancer.307
Randomized phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen in anti-angiogenic naïve patients with metastatic renal cell carcinoma (mRCC): Final analy304
Single cell phenotyping of PDL1 and HLA1 on circulating tumor cells (CTC) in clear cell renal cell carcinoma (ccRCC) on systemic treatment with immunotherapy (IO) and vascular endothelial growth facto303
NETOS: A personalized approach of neoadjuvant therapy, including INCB099280 monotherapy and bladder preservation, for muscle-invasive urothelial bladder carcinoma (MIBC) with ctDNA monitoring.300
Preference-weighted quality of life: Findings from the Selenium and Vitamin E Cancer Prevention Trial (SELECT).295
A phase Ⅱ, non-randomized, prospective trial of biweekly nab-paclitaxel in combination with ramucirumab for patients with previously treated advanced gastric or gastroesophageal junction cancer: B-RAX288
Exploratory analysis of biomarkers of response to durvalumab in advanced HER2-negative oesophago-gastric adenocarcinoma within a phase 2 clinical trial.285
Progression pattern and post-progression survival following atezolizumab and bevacizumab treatment in advanced hepatocellular carcinoma.270
Liver steatosis and fibrosis as independent prognostic factors affecting survival in colorectal cancer with liver metastases.268
Clinical characteristics and outcomes of patients with metastatic colitis-associated cancer treated with EGFR inhibitors.267
Ground-glass opacity showed response to immunotherapy in cancer patients.261
The role of exosomal LINC00853 in gastric cancer progression.258
Consistency and heterogeneity of microsatellite instability (MSI) status in paired biopsy and surgical specimens of colorectal cancer: A necessity for MSI reassessment after treatment?257
The power of glycobiology: Precision of polyp detection using glycoproteomic biomarkers.251
Prognostic impact of local recurrence and timing of palliative radiotherapy in patients with unresectable recurrent rectal cancer.250
A phase II trial of TAS-102 in patients with colorectal cancer with ctDNA-defined minimal residual disease post-adjuvant therapy: Results from the MD Anderson INTERCEPT Program.247
Assessing disparities in pancreatic cancer outcomes in African Americans.242
Immune-related adverse events in patients with gastrointestinal cancer undergoing pembrolizumab monotherapy: A systematic review of clinical trials.241
Genetic testing of Japanese patients with serrated polyposis syndrome: A multicentric study.237
Characterizing the rare abdominal neoplasms of peritoneum, retroperitoneum, and overlapping sites of peritoneum and retroperitoneum: A review of NCDB database.237
A combined phase I/II study of a novel bicycle tumor-targeted immune cell agonist BT7480 in patients with nectin-4 associated advanced malignancies.235
Assessing the impact of hypercalcemia of malignancy on clinical outcomes in cancer patients admitted with acute pancreatitis.233
Association of circulating T lymphocytes and their functional states with pathologic complete response (pCR) in breast cancer (BC). A prospective Italian study.230
Underutilization of standard of care (SOC) treatment intensification in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) by specialty.230
Implementation of a virtual tumor board through VA National TeleOncology service.227
Efficacy of alpelisib (ALP) + fulvestrant (FUL) with rational use of metformin (MET) in patients with HR+/HER2- advanced breast cancer (ABC).225
Using an AI trial screening tool to assess language as a barrier for enrollment of underrepresented minorities in cancer clinical trials.224
Expanding diversity in colorectal cancer studies with a focus on Hispanic and Latino participant enrollment.222
Abemaciclib dose escalation to maintain intensity (ADE-MI).219
Factors associated with delays in care of suspicious lung nodules at an academic medical center.217
Mobilizing exercise recommendations for people with bone metastases: An experience-based co-design approach.215
Impact on biomarker documentation in community oncology by optimizing clinical decision support.214
Three-year follow-up of outcomes with KTE-X19 in patients with relapsed/refractory mantle cell lymphoma in ZUMA-2.211
Circulating tumor DNA (ctDNA) and late recurrence in high-risk, hormone receptor–positive, HER2-negative breast cancer (CHiRP).210
Natural language processing for automated breast cancer recurrence detection and classification in computed tomography reports.207
Predictors of response and surgical approach after neoadjuvant chemotherapy in receptor-positive/HER2-negative stage II-III breast cancer patients treated in two private cancer care centers in Lima, P204
Effects of socioeconomic status (SES) and healthcare resource (HCR) availability on survival in Black patients (pts) versus (vs) White pts with multiple myeloma (MM): A SEER Medicare analysis.202
Breast cancer outcomes and treatment toxicity in geriatric patients compared to other patients at the Cancer Disease Hospital in Zambia.201
Disparities in incidence and mortality of hematologic cancers in Southeast Asia: A 2020 analysis.200
Enrollment of older adults in clinical trials for oncology indications, 2010-2020: An evaluation by the FDA.198
NSQIP audit of enhanced recovery after surgery protocols for radical cystectomy.198
Financial toxicity (FT), quality of life (QoL), and medication adherence patient-reported outcomes (PROs) in CLL on first-line (1L) oral oncolytics.195
Incorporating precision oncology in everyday clinical practice: First two years of comprehensive genomic profiling (CGP) testing experience in Croatia.194
A novel multi-cancer screening approach based on screening objectives, cancer occurrence mechanism, and cost modeling.193
A phase I/II trial of neoadjuvant pegylated arginine deiminase (ADI-PEG 20) with ifosfamide and radiotherapy in soft tissue sarcomas (STS) of the trunk or extremity.192
Commercial health plan spending on oncology drugs approved via the accelerated approval pathway and later withdrawn from the market.192
Efficacy of mammography screening in women aged 40–49 years: An updated systematic review and meta-analysis.191
Implementation of video assisted point-of-care germline genetic education and testing for patients with peri-diagnostic pancreatic cancer.190
Universal germline testing for cancer susceptibility and actionable noncancer disorders among 19,842 patients: Initial findings from the City of Hope INSPIRE study.189
Phase II study of anlotinib plus durvalumab and chemotherapy as first-line treatment in extensive-stage small cell lung cancer (ES-SCLC): Efficacy and safety analysis.189
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: Impact on health-related quality of life in RATIONALE-301 population.189
Adherence and perception of the importance of anti-COVID-19 protective measures amongst patients with cancer.186
Effect of IL-15 on anti-tumor immune response to radio-immunotherapy through systemic immune activation.185
Effect of war on radiotherapy in Ukraine and how to help.184
PIK3CA testing and treatment patterns among patients with metastatic breast cancer in US community clinical practice.184
Pelareorep driven blood TIL expansion in patients with pancreatic, breast and colon cancer.183
Predictors of long-term survival in immune checkpoint inhibitor (ICI)-associated myocarditis.182
The role of folate receptor-positive circulating tumor cells in the prognosis analysis of esophageal squamous cell carcinomas.182
Imlunestrant, an oral selective estrogen receptor degrader (SERD), in combination with human epidermal growth factor receptor 2 (HER2) directed therapy, with or without abemaciclib, in estrogen recept181
pionERA Breast Cancer (BC): Phase III study of first-line (1L) giredestrant vs. fulvestrant, both combined with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i), in patients (pts) with estrogen recep181
Feasibility of implementing whole genome sequencing into routine oncology care.180
Immune checkpoint inhibitor (ICI) rechallenge after immune-related adverse events (irAE) requiring hospitalization: A single-center 10-year experience.176
Dual-agent immunotherapy for prevention of melanoma brain metastases: A real-world analysis of 8686 patients.175
Real-world impact of KRAS mutations on clinical outcomes in metastatic colorectal cancer treated with trifluridine-tipiracil in the USA.173
Genomic profile in Mexican women with early-stage breast cancer using Mammaprint+Blueprint assay: A retrospective study.168
Relationship between immune-inflammatory markers and clinical features and deepness of tumor response and prognosis of patients with PD-L1 ≥50% metastatic NSCLC receiving first-line immunotherapy.168
Benmelstobart (TQB2450) combined with anlotinib hydrochloride capsule in the treatment of advanced, recurrent, or metastatic endometrial cancer: A multicohort, open label, multicenter, phase II clinic168
COBRA: Assessment of safety and efficacy of 64Cu-SAR-bisPSMA in patients with biochemical recurrence of prostate cancer following definitive therapy.165
Avelumab with axitinib in persistent or recurrent cervical cancer after platinum-based chemotherapy (ALARICE study).164
HDAC I/IIb selective inhibitor purinostat mesylate in relapsed and refractory diffuse large B-cell lymphoma: A single agent phase IIa trial.164
Consistent data about the predictive factors of the success of interval debulking surgery (CC0-IDS) in patients with advanced ovarian cancers in two large independent datasets.162
VAMANA: A phase 2 study of low-dose bevacizumab plus CCNU in relapsed/recurrent glioblastoma.161
A phase 1, multi-center, open-label, dose-escalation, and dose-expansion study of CBP-1018, a bi-ligand-drug conjugate in patients with heavily treated advanced solid tumors.160
Informed decision-making about germline testing among Veterans with advanced prostate cancer (APC): A mixed-methods study.158
Correlation of body mass index (BMI) with survival outcomes in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Analysis of patient (pt)-level data from SWOG 1216 study.156
Efficacy and safety of combination therapy with envafolimab and lenvatinib in patients with endometrial cancer after failure of first-line platinum-based therapy.154
Genomic instability is enriched in localized prostate cancers from men of African ancestry.154
Gemcitabine/paclitaxel/adriamycin (GTA) as a nephron-sparing regimen in urothelial carcinoma: The MD Anderson Cancer Center (MDACC) experience.154
The influence of access to care on radiation therapy utilization among older women with breast cancer.153
Effect of sodium-glucose cotransporter 2 inhibitor dapagliflozin on systemic H-FABP and monocyte-to-lymphocyte ratio in preclinical models of antracycline induced cardiotoxicity.152
Real-world experience with CDK4/6 inhibitors in the first-line palliative setting for HR+/HER2- advanced breast cancer.152
Upstream regulation of neurotransmitter signaling genes in metastatic colorectal cancer (mCRC) patients: Data from CALGB/SWOG 80405 trial (Alliance) and MONSTAR-SCREEN-2.151
Use of Oncotype vs. Breast Cancer Index (BCI) for extended endocrine therapy decisions: A single center analysis in stage IA hormone receptor positive breast cancer.151
Clinical outcomes with alpelisib (ALP) plus fulvestrant (FUL) in patients with HR-positive (HR+)/HER2-negative (HER2-) advanced breast cancer (ABC) with PIK3CA mutations (m) in routine practice149
Overall survival with palbociclib (PAL) plus an aromatase inhibitor (AI) versus AI alone in older patients (pts) with de novo, HR+/HER2− metastatic breast cancer: A SEER-Medicare analysis.148
Incidence of infusion related reactions of daratumumab-hyaluronidase-fihj: Pre-post intervention study of premedication omission.147
Use of integrated multi-omics analysis to determine antitumor efficacy of donafenib in combination with FADS2 inhibition in hepatocellular carcinoma.147
Clinical and translational results from REVOLUTION cohorts A (nivolumab + ipilimumab + chemotherapy) and B (hydroxychloroquine + ipilimumab + chemotherapy) in patients with previously untreated metast145
A phase 2 study to determine the pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in stage I to III resectable Merkel cell carcinoma (Neo-MCC).145
Association of CDX2 expression with clinical, pathologic, and molecular features in MSI-H colorectal cancer.144
Primary retroperitoneal lymph node dissection (RPLND) in seminoma stage IIA-IIC ≤3cm: Combined results of the SWENOTECA (Swedish Norwegian Testicular Cancer Group) and Cologne.143
Randomized phase II study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms143
Risk of VTE in TNBC treated with neoadjuvant immunotherapy.143
Comparison of real-world mortality data among patients with glioblastoma (GBM) and metastatic pancreatic cancer (mPC) treated in the community oncology setting.143
Relationship of adaptive subtyping and tumour heterogeneity of treatment response to neoadjuvant therapy in hormone receptor–positive HER2-negative early breast cancer: PENELOPE-B.139
Does the time-of-day administration of immune checkpoint inhibitors affect efficacy in patients with metastatic renal cell carcinoma? A single-center study.139
A real-world study of anlotinib in combination with PD-L1 inhibitors plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer.138
Real world experience of bispecific fusion protein in patients with metastatic uveal melanoma: Can we deliver?138
Oncology-specific Qualified Clinical Data Registry (QCDR) measures to advance cancer care and achieve Merit-Based Incentive Payment System (MIPS) performance.136
Multicentric retrospective study on the treatment characteristics, efficacy and safety of eribulin in Slovenian patients with breast cancer.136
Multiomic characterization to reveal a distinct molecular landscape in young-onset pancreatic cancer.136
Real-world racial disparities in EGFR testing and third-generation EGFR TKI use among U.S. patients with stage IV NSCLC.135
Dendrimer-enhanced (DEP) SN38 (DEP irinotecan) in patients (pts) with advanced solid tumors: A phase 1/2 trial.135
Axillary pathologic response after neoadjuvant chemotherapy and surgery according to breast cancers subtypes and survival impact.135
Neoadjuvant chemotherapy (NAC) followed by total mesorectal excision (TME) and adjuvant chemotherapy versus TME followed by adjuvant chemotherapy in very low-lying clinical (c) T3 rectal cancer (NAIR)135
Final analysis of a prospective controlled trial of the efficacy of uracil and tegafur/leucovorin for stage II colon cancer with risk factors for recurrence using propensity score-based methods (JFMC4134
SCORE: A multisite randomised controlled trial evaluating shared care for colorectal cancer survivors.134
A prospective study exploring the safety and efficacy of lenvatinib for patients with advanced hepatocellular carcinoma potential in current real-world practice.134
Quality initiative (QI) to improve molecular testing in newly diagnosed (ND) stage 4 non-small cell lung cancer (NSCLC-4): An Integra Connect (IC) database study.134
0.037977933883667